Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alt-l9
- Development stage
- Phase 1
- Lead developer
- Alteogen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
ALT-L9 is a biosimilar of aflibercept (originator brand name Eylea), developed by Alteogen and its subsidiary Altos Biologics. It is a recombinant fusion protein designed to inhibit vascular endothelial growth factor A (VEGF-A) and placental growth factor (PIGF), thereby suppressing neovascularization and reducing vascular permeability in the eye. The drug is intended for the treatment of wet age-related macular degeneration (wet AMD). ALT-L9 has demonstrated therapeutic equivalence to Eylea in phase 3 clinical trials involving over 400 participants across 12 countries. The formulation features improved thermal stability compared to the originator, potentially offering a longer shelf life[1][2][3][4][5][6][7][9][10].
- Other names
- aflibercept biosimilareylea biosimilar
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on alt-l9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alt-l9.